Table 2.
Status of different types of COVID-19 vaccines.
| S.No | Type of vaccine | Name | Developer | Trial phase | Registration number/Clinical trial number |
|---|---|---|---|---|---|
| 1. | RNA-based vaccine | BNT162 | Pfizer/BioNTech | Phase 3 | NCT04368728 |
| 2. | mRNA-based vaccine | mRNA 1273 | Moderna | Phase 3 | NCT04283461 |
| 3. | Viral vectored vaccine | Inactivated vaccine | Wuhan Institute of Biological Products, China National Pharmaceutical group (Sinopharm) | Phase 3 | ChiCTR2000031809 |
| 4. | Adenovirus-based vaccine | Ad5-nCoV | CanSino Biologics | Phase 3 | NCT04313127 |
| 5. | Inactivated vaccine | CoronaVac | Sinovac | Phase 3 | NCT04456595 |
| 6. | Adenovirus vectored vaccine | ChAdOx1 nCoV-19 or Covidshield |
The University of Oxford | Phase 3 | NCT04324606 |
| 7. | Adenovirus vectored vaccine | Sputnik V | Gamaleya Research Institute of epidiomology and Microbiology, Health Ministry of the Russian Federation | Phase 3 | NCT04530396 |
| 8. | Recombinant vaccine | NVX-CoV2373 | Novavax | Phase 3 | NCT04533399 |
| 9. | Whole virion inactivated vaccine | Covaxin | Bharat Biotech | Phase 3 | NCT04471519 |
| 10. | Inactivated vaccine | BBIBP-CorV | Beijing Institute of Biological Products, China National Pharmaceutical group (Sinopharm) | Phase1/2 | – |
| 11. | DNA vaccine | GX-19 | Genexine | Phase 1/2 | NCT04445389 |
| 12. | mRNA-based vaccine | LUNAR-COV19 | Arcturus Therapeutics and Duke-NUS Medical School | Phase 1/2 | – |
| 13. | DNA vaccine | INO-4800 | Inovio Pharmaceuticals | Phase 1/2 | NCT04447781 |
| 14. | mRNA-based vaccine | CVnCoV | CureVac | Phase 1 | NCT04515147 |
| 15. | Recombinant subunit vaccine | SCB-2019 | Clover Biopharmaceuticals | Phase 1 | NCT04405908 |
| 16. | Recombinant vaccine | COVAX-19 | Vaxine Pty Ltd. | Phase 1 | NCT04453852 |
| 17. | Recombinant vaccine | Plant-based adjutant COVID-19 vaccine | Medicago | Phase 1 | NCT04450004 |
| 18. | Lentivirus vector vaccine | COVID-19 aAPC | Shenzhen Geno-Immune Medical Institute | Phase 1 | NCT04299724 |